Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
First, Celcuity is now Boxer Capital’s fifth-largest position, with 225,000 shares owned, valued at a total of $22.44 million.
Second, while this is an aggressive — and bullish — move by Boxer Capital, it’s not one that should be blindly copied by all, or even most, retail investors. Here’s why.
Celcuity is a biotech stock. That means the company is engaged in the process of developing treatments for disease. Specifically, Celcuity focuses on the treatment of cancer. This work is high-risk and high-reward. Biotech companies tend to invest heavily in research and development. If their treatments are effective and receive approval from government oversight panels, they can produce enormous profits, leading to soaring stock prices. On the other hand, disappointing clinical trial data or failing to secure government approval can lead to a tumbling stock price.
In other words, this sector is volatile — meaning its not for every investor. Indeed, even aggressive investors may be wise to spread their risk through a biotech ETF, rather than put all their eggs in one basket.
Should you buy stock in Celcuity right now?
Before you buy stock in Celcuity, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Celcuity wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $534,817!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,123,912!*
Now, it’s worth noting Stock Advisor’s total average return is 964% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 6, 2026.
Jake Lerch has no position in any of the stocks mentioned. The Motley Fool recommends Kymera Therapeutics. The Motley Fool has a disclosure policy.
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing was originally published by The Motley Fool
Content Original Link:
" target="_blank">
